Search Results
Your search for ,New matches 16916 pages
Showing 3851 - 3900
Benoit You, MD, PhD, on Endometrial Cancer: New Data on Combining Olaparib, Cyclophosphamide, and Metformin
Benoit You, MD, PhD, of the Lyon University Hospital (France), discusses phase I/II safety and efficacy results from the ENDOLA trial that combined olaparib with metronomic cyclophosphamide and metformin in patients with advanced pretreated endometrial cancer. At 10 weeks, the non–disease...
Alana L. Welm, PhD, on Metastatic Outgrowth in the Lungs: Identifying a New Immune-Mediated Pathway
Alana L. Welm, PhD, of the University of Utah Huntsman Cancer Institute, discusses her findings of a new pathway that regulates the antitumor immune response during metastatic outgrowth. Interfering with a particular isoform of RON kinase may cause metastatic tumors to be swarmed by T cells and...
Deciphering Clinical Outcomes Through Molecular Profiling: The IMmotion151 Trial
Over the past decade, an improved understanding of kidney cancer biology together with the development of novel systemic therapies have substantially improved the outcomes of patients with metastatic clear cell renal cell carcinoma (RCC).1 Following extensive clinical investigations, combinations...
Reflections on the Evolution of Clinical Care Since the Passage of the National Cancer Act of 1971
Recently, I had the honor of coauthoring a chapter with Eric P. Winer, MD, President-Elect of ASCO, on the evolution of clinical cancer care since the enactment of the National Care Act of 1971 for the book A New Deal for Cancer: Lessons From a 50-Year War, by Abbe R. Gluck and Charles S. Fuchs,...
Expert Point of View: Mark E. Robson, MD
“OlympiA is clearly a practice-changing trial, and olaparib should be offered to patients meeting the entry criteria for the study,” said Mark E. Robson, MD, Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York. Dr. Robson was invited to discuss the findings of...
OlympiA Trial: Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer
The OlympiA trial of adjuvant olaparib in patients with HER2-negative, high-risk early-stage breast cancer and BRCA1 and BRCA2 mutations has now demonstrated a significant overall survival benefit, reducing the risk of death over placebo by 32% and yielding an absolute improvement of 3.8% at 3...
Congress Increases Federal Funding for Cancer Research
President Biden is soon expected to sign into law the Fiscal Year (FY) 2022 omnibus funding bill, which provides funding for all federal agencies through September 30, 2022. The bill was passed by the U.S. House of Representatives and the U.S. Senate during the week of March 7, 2022. The bill...
Rapid Guideline Revises Recommendations for Adjuvant Therapy in Patients With Early-Stage Lung Cancer
A rapid recommendation update to an ASCO guideline offers revised parameters for adjuvant therapy in patients with resected non–small cell lung cancer (NSCLC) who have stage IB to IIIA disease.1,2 The new guidance reflects the findings from two randomized clinical trials that assessed the use of...
Supporting and Mobilizing Resources: ASCO Joins Worldwide Efforts to Support Ukrainian Cancer Care
“Refugees and displaced people may see their cancer treatment interrupted, or they may develop a new cancer while they are in host countries. They often present with advanced disease and suffer more complications. These patients have poor outcomes because of poor hygiene and living conditions, as...
ASCO Provisional Clinical Opinion Offers Guidance for Using and Interpreting Genomic Testing in Patients With Advanced Cancer
Somatic genomic testing should be a routine part of clinical care for many patients with metastatic or advanced solid tumors, according to a new ASCO provisional clinical opinion.1 As reported in the Journal of Clinical Oncology, the expert panel found that genomic testing in oncology practice has...
Leader in the Field of Integrative Oncology, Barrie Cassileth, PhD, Dies at 83
In 1999, Memorial Sloan Kettering Cancer Center (MSK) President Paul Marks, MD, recruited Barrie Cassileth, PhD, to establish an Integrative Medicine Service that “provided evidence-based complementary therapies that improve patients’ quality of life by alleviating physical and emotional symptoms...
Childhood Leukemia Pioneer, Donald P. Pinkel, MD, Dies at 95
When St. Jude Children’s Research Hospital was opened in 1962, childhood blood cancer, especially acute lymphoblastic leukemia (ALL), had an exceptionally grim prognosis. However, years of unflagging clinical research led by Donald P. Pinkel, MD, the pediatrician who developed an aggressive...
National Brain Tumor Society Launches DNA Damage Response Consortium With Yale Cancer Center
The National Brain Tumor Society (NBTS) announced the launch of its new flagship research initiative, the DNA Damage Response Consortium, in partnership with Yale Cancer Center. The consortium will bring together a diverse team of adult and pediatric researchers to advance a new class of potential...
Having Metastatic Breast Cancer Has Led Me to Focus on What Matters
Nothing can really prepare you for cancer, but it helped that I have dedicated my life in service to others as a minister and advocate for social justice and health equity in breast cancer survivorship. Before my own breast cancer diagnosis in 2016, I had spent years as a volunteer for several...
Use of Traditional Chinese Medicine Herbal Formula Xiao Yao San to Relieve Depression and Anxiety
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on ...
A Lifetime of Pioneering Biologic Research Leads to a New History of Evolution
Although The Social Conquest of Earth was published a decade ago, it is worth revisiting, because, as oncology luminary Harold Varmus, MD, stressed: “It is a tour de force that we ignore at our planet’s peril.” Its author, Edward O. Wilson, PhD, known as “the father of sociobiology,” died at the...
Conundrums of SARS–CoV-2 Infection in Cancer Care
The ASCO Post is pleased to present the Hematology Expert Review, an occasional feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib, Kröger, and Mikulska focus on the challenges of providing cancer care amid the COVID-19 pandemic. Here they present two...
Jeffrey Peppercorn, MD, MPH, Named Editor-in-Chief of JCO Oncology Practice
Jeffrey Peppercorn, MD, MPH, has been appointed as the next Editor-in-Chief of the ASCO journal JCO Oncology Practice (JCO OP). The journal publishes impactful information and insights to keep oncology practice current on changes and challenges inherent in delivering equitable, high-quality...
Seven New Research Grants Awarded by The Prevent Cancer Foundation
The Prevent Cancer Foundation recently announced funding for seven scientists who are researching cancer prevention and early detection. Each scientist has been awarded $100,000 for 2 years. The following individuals are the 2022 research grantees: Sarah Bernhardt, PhD, Postdoctoral Fellow Oregon...
RELATIVITY-047: Relatlimab Plus Nivolumab Worthy of Further Study in Advanced Melanoma and Beyond
In the recently published results of the RELATIVITY-047 trial,1 summarized in this issue of The ASCO Post, the addition of relatlimab to nivolumab monotherapy was associated with improved progression-free survival compared with nivolumab alone in patients with previously untreated advanced,...
Addition of Anti–LAG-3 Antibody Relatlimab to Nivolumab Improves Progression-Free Survival in Previously Untreated Advanced Melanoma
In a phase II/III trial (RELATIVITY-047) reported in The New England Journal of Medicine, Hussein A. Tawbi, MD, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues found that the addition of relatlimab, a lymphocyte-activation gene 3 (LAG-3)–blocking antibody, to nivolumab...
City of Hope Completes Strategic Acquisition of Cancer Treatment Centers of America
On February 2, 2022, City of Hope announced that it has completed its previously announced acquisition of Cancer Treatment Centers of America (CTCA), a network of oncology hospitals and outpatient care centers across the United States. City of Hope, in Duarte, California, now has expanded its...
The Hamoui Foundation and LUNGevity Foundation Present Awards for RET-Positive Lung Cancer Research
The Hamoui Foundation and LUNGevity Foundation recently announced the 2022 recipients of the first The Hamoui Foundation/LUNGevity Clinical Research Award for RET-Positive Lung Cancer. RET is a driver mutation found in approximately 1% to 2% of people with non–small cell lung cancer. The goal of...
Thomas W. Flaig, MD, on Bladder Cancer: New Treatment Options
Thomas W. Flaig, MD, of the University of Colorado Cancer Center, discusses the rapidly changing treatment landscape for patients with bladder cancer, including PD-1 and PD-L1 inhibitors now approved for urothelial carcinoma; a category 1 indication for pembrolizumab in metastatic disease,...
Margaret A. Tempero, MD, on Pancreatic Adenocarcinoma: Emerging Systemic Therapy Options
Margaret A. Tempero, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the most effective ways to use the regimens available to treat patients with pancreatic cancer (FOLFIRINOX [fluorouracil, leucovorin, irinotecan, and oxaliplatin] and...
Screening Platform May Contribute to Detection of Early-Stage Pancreatic Cancers, Other Malignancies
A novel screening platform flagged more than 95% of stage I pancreatic cancers, in addition to other early-stage malignancies, according to a pilot study published by Hinestrosa et al in Nature Communications Medicine. If validated by future studies, the approach may offer a new way to detect the...
Research Finds COVID-19 Vaccine Protects Most Patients With Cancer, but Risk Remains Higher for Patients With Blood Cancers
Using the nation’s largest COVID-19 data resource, a research team found that the COVID-19 vaccine offered protection for most patients with cancer. However, patients with certain types of cancer—especially those with hematologic malignancies—had a higher and widely varied risk of breakthrough...
Multilevel Factors Related to Changes in Body Adiposity in Black Survivors of Breast Cancer
In a study reported in the Journal of Clinical Oncology, Qin et al found that gains in body weight and body fat were common in a prospective cohort of Black breast cancer survivors. The researchers also identified factors associated with these changes. As stated by the investigators, “Unfavorable...
Study Identifies Decline in Annual Screening for Breast Cancer Survivors
New research published by Lowry et al in JNCCN—Journal of the National Comprehensive Cancer Network found the rate of mammography participation by breast cancer survivors has been steadily declining since 2009, particularly among younger survivors. The researchers reviewed a nationwide commercial...
No Overall Survival Benefit With Atezolizumab Plus Bevacizumab vs Sunitinib in Previously Untreated Metastatic Renal Cell Carcinoma
As reported in JAMA Oncology by Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, the final overall survival analysis of the phase III IMmotion151 trial has shown no significant difference for the PD-L1 inhibitor atezolizumab plus bevacizumab vs sunitinib in patients ...
Brazilian Oncologist Antônio Drauzio Varella, MD, Rises From the Streets of São Paulo to International Fame
In this edition of Living a Full Life, Guest Editor Jame Abraham, MD, spoke with Antônio Drauzio Varella, MD, a Brazilian oncologist, educator, scientist, and medical science popularizer in the press and television, as well as a best-selling author. Antônio Drauzio Varella, MD, was born in 1943 in ...
Positive Lymph Nodes May Not Be an Indicator for Chemotherapy in Older Patients With Breast Cancer
Positive lymph node status may not be a reliable indicator of the need for adjuvant chemotherapy, and sentinel node biopsy may be unnecessary in older women with certain low-risk cancers, according to a new study presented by Nicholson et al at the American Society of Breast Surgeons 23rd Annual...
Protecting the Immunocompromised From COVID-19: Practical Information for Physicians
COVID-19 may have caught the world off guard in 2020, but in the 2 years since the pandemic began, several effective monoclonal antibodies and antiviral drugs have emerged to protect the most vulnerable patients. The ASCO Post spoke with Gunjan L. Shah, MD, a hematologic oncologist at Memorial...
Trials of PARP Inhibitors in Urothelial Cancer: More Questions Than Answers?
Two studies presented at the 2022 ASCO Genitourinary Cancers Symposium explored the role of poly (ADP-ribose) polymerase (PARP) inhibitors in urothelial cancer: ATLANTIS and BAYOU.1,2 Results suggest that PARP inhibitors may be useful in certain genetic subgroups and perhaps in combination with...
Study Explores Racial Disparities Among Patients Undergoing Gastrointestinal Cancer Surgery
Black adult patients are more likely than White patients to receive substandard gastrointestinal cancer surgery, according to a large study led by researchers at Yale Cancer Center published by Bakkila et al in JAMA Network Open. “The COVID-19 pandemic has brought to light previously reported race...
Norman Sharpless, MD, to Step Down as Director of the NCI
Norman E. Sharpless, MD, has announced that he has decided to step down from his position as Director of the National Cancer Institute (NCI), part of the National Institutes of Health, a position he has held since 2017. Dr. Sharpless will continue as NCI Director through April 29, 2022, to allow...
Several Studies Evaluate Agents in the First-Line, Second-Line, and Later Treatment of Advanced Kidney Cancer
The combination of nivolumab plus cabozantinib achieved a continued survival benefit compared with sunitinib in patients with untreated clear cell metastatic or advanced renal cell carcinoma, according to a final overall survival analysis of the phase III CheckMate 9ER trial.1 Additionally,...
DESTINY-Breast03 Trial: T-DXd vs T-DM1 in Previously Treated Patients With Metastatic HER2-Positive Breast Cancer
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs ado-trastuzumab emtansine (T-DM1) in patients with...
Registry Study Shows a Real-World Increase in Biomarker Testing Among Patients With Advanced NSCLC
More than half of patients diagnosed with advanced non–small cell lung cancer (NSCLC) undergo biomarker testing, and this figure has increased over the past 5 years, according to real-world data from a Spanish national registry study reported by Calvo de Juan et al at the European Lung Cancer...
Emerging Endocrine Therapies for the Management of Breast Cancer
Novel hormonal therapies for breast cancer could provide additional therapeutic options for patients with hormone receptor–positive breast cancer. The emerging landscape for these new agents was described at the 2022 Miami Breast Cancer Conference, sponsored by PER, by Aditya Bardia, MD, MPH,...
Thickness-Specific Incidence of Cutaneous Melanoma in the United States
In a population-based cohort study reported in JAMA Oncology, Chen et al found that the incidence of overall cutaneous melanoma and thinner tumors was stable in the United States from 2010 to 2018, with an increased incidence of the thickest (T4) melanomas being observed. Lower socioeconomic status ...
Third COVID-19 Vaccine Dose May Improve Immune Response in Patients With Lymphoma
New research has found that the weakened immune systems of patients with lymphoma may improve after they receive a third COVID-19 vaccination. Patients with lymphoma have defects in their immune system that restrict its response to vaccination; despite this, a study published by Lim et al in Nature ...
How ASCO, ECO, and WHO Are Marshalling Resources to Provide Care for Ukrainian Civilians and Refugees With Cancer
Since Russia invaded Ukraine on February 24, the number of attacks on health-care facilities continues to mount. According to the World Health Organization (WHO), as of March 16, there have been 43 attacks on health facilities, including 34 attacks that have directly impacted health facilities and...
Expert Point of View: E. Gabriela Chiorean, MD
The invited discussant of the CodeBreaK 100 data, E. Gabriela Chiorean, MD, Professor of Medicine at the University of Washington and Fred Hutchinson Cancer Research Center, and Clinical Director of the Gastrointestinal Medical Oncology program at Seattle Cancer Care Alliance, found the efficacy of ...
Expert Point of View: Mandana Kamgar, MD, MPH
The ASCO Post invited Mandana Kamgar, MD, MPH, Assistant Professor of Medicine at the Medical College of Wisconsin, LaBahn Pancreatic Cancer Program, Milwaukee, to comment on the KRYSTAL-1 trial. “The KRYSTAL-1 study in totality is a multiphase and multiarm ongoing study exploring the role of...
Expert Point of View: Anthony El-Khoueiry, MD
Anthony El-Khoueiry, MD, Member of the Section of Gastrointestinal Cancers, Director of the phase I program, and Associate Professor of Clinical Medicine at the Keck School of Medicine of the University of Southern California and USC Norris Comprehensive Cancer Center, said the findings of the...
HIMALAYA Trial: First-Line Tremelimumab Plus Durvalumab Improves Overall Survival in Unresectable Hepatocellular Carcinoma
Patients with advanced, unresectable hepatocellular carcinoma may be gaining another first-line treatment option. In the global phase III HIMALAYA trial, a single priming dose of tremelimumab plus regular-interval durvalumab significantly improved overall survival, according to Ghassan K....
Expert Point of View: Ian Chau, MD
Invited discussant Ian Chau, MD, Consultant Medical Oncologist at The Royal Marsden Hospital in London and Surrey in the United Kingdom, said the findings from COSMIC-312 are not mature enough to establish cabozantinib/atezolizumab as a new front-line option for advanced hepatocellular carcinoma...
COSMIC-312: Cabozantinib Plus Atezolizumab Improves Progression-Free Survival in Advanced Hepatocellular Carcinoma
The phase III COSMIC-312 study has met its primary endpoint, showing a significant improvement in progression-free survival with cabozantinib plus atezolizumab compared with sorafenib in treatment-naive hepatocellular carcinoma (HCC), investigators reported at a European Society for Medical...
Expert Point of View: Chris Verslype, MD, PhD
The invited discussant of the RATIONALE 208 trial, Chris Verslype, MD, PhD, Professor of Medicine at University Hospitals Leuven in Belgium, said tislelizumab is an “active and safe” investigational PD-1 antibody, “comparable to other PD-1 agents.” In particular, he noted, the results of RATIONALE...
